TY - JOUR T1 - Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3723 VL - 58 IS - suppl 65 SP - PA3723 AU - Mark Gurnell AU - Liam G. Heaney AU - Andrew Menzies-Gow AU - Jonathan Corren AU - Elisabeth H. Bel AU - Jorge Maspero AU - Timothy Harrison AU - David J. Jackson AU - David Price AU - Njira Lugogo AU - Annie Burden AU - Alex De Giorgio-Miller AU - Kelly Padilla AU - Ubaldo J. Martin AU - Esther Garcia Gil AU - James Kreindler Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3723.abstract N2 - Introduction: Patients with severe eosinophilic asthma are often oral corticosteroid (OCS) dependent, leading to adrenal insufficiency (AI). PONENTE evaluated the ability of benralizumab-treated patients to reduce maintenance OCS by monitoring adrenal status: a personalized OCS-reduction phase based on initial OCS dosage, asthma control, and adrenal function was followed by a 24- to 32-week maintenance phase.Aim: To assess adrenal function recovery at the end of the maintenance phase in patients with partial or complete AI.Methods: Patients continued the lowest stable daily OCS dosage or OCS elimination achieved during the reduction phase plus benralizumab 30 mg every 8 weeks for 3 doses. Adrenal status was assessed upon reaching 5 mg stable OCS dosage during the reduction phase and repeated through to the end of the maintenance phase depending on adrenal status as described in the protocol.Results: Of 598 patients who entered PONENTE, 90% completed the OCS-reduction and maintenance phases. Most patients maintained or improved adrenal status (Figure 1). At the end of the maintenance phase, 55.5% of patients had normal adrenal function.Conclusions: PONENTE demonstrates that OCS-dependent, benralizumab-treated asthma patients with partial AI and even complete AI can recover normal adrenal function during and after OCS elimination or tapering. FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3723.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -